Biobanks are important resources for improving public health and individual care. Some legal frameworks can be more or less conducive to advancing the potential benefits of biobanks. The purpose of this article is to assess biobanking legislation and practices in Spain to determine how well they fare in such a regard. We focus here on some of the primary ethical values that ground relevant legislation and that we believe are consistent with promoting biobanking benefits: the value of scientific research; efficient use of scarce resources; and respect for the dignity of donors. We argue that although Spanish regulations advance these values in important ways, they also have provisions that undermine them and thus risk limiting the potential benefits of biobanks. We offer some suggestions for improvement.
Get full access to this article
View all access options for this article.
References
1.
Al DiffalhaS, SextonKC, WatsonPH, et al.The importance of human tissue bioresources in advancing biomedical research. Biopreserv Biobank, 2019; 17(3):209–212; doi: 10.1089/bio.2019.0039
2.
PatrinosD, KleidermanE, FraserW, et al.Developing policy for the healthy life trajectories initiative: Going from National to International. Biopreserv Biobank, 2023; In Press; doi: 10.1089/bio.2022.0198
3.
DevereuxL, WatsonPH, Mes-MassonA-M, et al.A review of international biobanks and networks: Success factors and key benchmarks—A 10-year retrospective review. Biopreserv Biobank, 2019; 17(6):512–519; doi: 10.1089/bio.2019.29060.djc.SI
4.
Simeon-DubachD, RoehrlMH, HofmanP, et al.Enhancing cooperation between academic biobanks and biomedical industry: Better mutual understanding and new collaborative models are needed. Biopreserv Biobank, 2020; 18(2):144–149; doi: 10.1089/bio.2019.0095
5.
WeilCJ.Ethical, legal, and policy issues surrounding biospecimen research conducted or supported in the USA. Biopreserv Biobank, 2023; 21(1):14–22; doi: 10.1089/bio.2021.0094
6.
VodosinP, JorgensenAK, MendyM, et al.A review of regulatory frameworks governing biobanking in the low and middle income member countries of BCNet. Biopreserv Biobank, 2021; 19(5):444–452; doi: 10.1089/bio.2020.0101
7.
BledsoeMJ.Ethical legal and social issues of biobanking: Past, present, and future. Biopreserv Biobank, 2017; 15(2):142–147; doi: 10.1089/bio.2017.0030
8.
BeierK, LenkC. Biobanking strategies and regulative approaches in the EU: Recent perspectives. J Biorepos Sci Appl Med, 2015; 3:69–81.
Royal Decree 1716/2011, November 18, 2011 Establishing the Basic Authorization and Operation Requirements for Biobanks for the Purpose of Biomedical Research and for the Handling of Biological Samples of Human Origin, and Regulates the Operation and Organization of the National Biobank Registry for Biomedical Research. Available from: https://www.boe.es/buscar/act.php?id=BOE-A-2011-18919 [Last accessed: November 22, 2023].
EdsallJT.Scientific Freedom and Responsibility—Report of Aaas Committee on Scientific Freedom and Responsibility. Science, 1975; 188(4189):687–693; doi: 10.1126/science.11643270
13.
VaughtJ.Biobanking Comes of Age: The Transition to Biospecimen Science. Annu Rev Pharmacol Toxicol, 2016; 56:211–228; doi: 10.1146/annurev-pharmtox-010715-103246
14.
LanghofH, KahrassH, SieversS, et al.Access policies in biobank research: What criteria do they include and how publicly available are they? A cross-sectional study. Eur J Hum Genet, 2017; 25(3):293–300; doi: 10.1038/ejhg.2016.172
15.
GrankvistK, GomezR, NyboM, et al.Preanalytical aspects on short- and long-term storage of serum and plasma. Diagnosis, 2019; 6(1):51–56; doi: 10.1515/dx-2018-0037
16.
LeeJE, KimYY. Impact of preanalytical variations in blood-derived biospecimens on Omics studies: Toward precision biobanking?. Omics, 2017; 21(9):499–508; doi: 10.1089/omi.2017.0109
17.
StevensVL, HooverE, WangY, et al.Pre-analytical factors that affect metabolite stability in human urine, plasma, and serum: A review. Metabolites, 2019; 9(8):156; doi: 10.3390/metabo9080156
18.
DomaradzkiJ, PawlikowskiJ. Public attitudes toward biobanking of human biological material for research purposes: A literature review. Int J Environ Res Public Health, 2019; 16(12):2209; doi: 10.3390/ijerph16122209
19.
DiveL, CritchleyC, OtlowskiM, et al.Public trust and global biobank networks. BMC Med Ethics, 2020; 21(1):73; doi: 10.1186/s12910-020-00515-0
20.
MilneR, MorleyKI, AlmarriMA, et al.Demonstrating trustworthiness when collecting and sharing genomic data: Public views across 22 countries. Genome Med, 2021; 13(1):92; doi: 10.1186/s13073-021-00903-0
21.
HendersonMK, GoldringK, Simeon-DubachD. Advancing professionalization of biobank business operations: Performance and utilization. Biopreserv Biobank, 2019; 17(3):213–218; doi: 10.1089/bio.2019.0005
22.
BledsoeMJ, SextonKC. Ensuring effective utilization of biospecimens: Design, marketing, and other important approaches. Biopreserv Biobank, 2019; 17(3):248–257; doi: 10.1089/bio.2019.0007
23.
BalazV, JeckT, BalogM. Economics of biobanking: Business or public good? Literature review, structural and thematic analysis. Soc Sci Basel, 2022; 11(7):288; doi: 10.3390/socsci11070288
24.
HendersonM, Simeon-DubachD, AlbertM. Finding the path to biobank sustainability through sound business planning. Biopreserv Biobank, 2015; 13(6):385–386; doi: 10.1089/bio.2015.29039.mh
25.
SamuelG, HardcastleF, LucassenA. Environmental sustainability and biobanking: A pilot study of the field. New Genet Soc, 2022; 41(2):157–175; doi: 10.1080/14636778.2022.2093707
26.
QuinnCM, PorwalM, MeagherNS, et al.Moving with the times: The Health Science Alliance (HSA) biobank, pathway to sustainability. Biomark Insights, 2021; 16:11772719211005745; doi:10.1177/11772719211005745
27.
Van AsscheK, SterckxS.The Protection of Human Dignity in Research Involving Human Body Material. In: Humanity Across International Law and Biolaw. (Van BeersB, CorriasL, WernerW. eds.) Cambridge University Press: Cambridge; 2013; pp. 265–287.
28.
FosterC.Human Dignity in Bioethics and Law. Hart Publishing; Oxford: Portland, OR; 2011.
29.
DolléL, BekaertS. High-quality biobanks: Pivotal assets for reproducibility of OMICS-Data in Biomedical Translational Research. Proteomics, 2019; 19(21–22):e1800485; doi: 10.1002/pmic.201800485
